Selective internal radiation therapy (sirt) as conversion therapy for unresectable primary liver malignancies

Liver Cancer

Volumn 5, Issue 4, 2016, Pages 303-311

  Cucchetti, Alessandro ^a   Cappelli, Alberta ^a   Ercolani, Giorgio ^a   Mosconi, Cristina ^a   Cescon, Matteo ^a   Golfieri, Rita ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cholangiocellular carcinoma; hepatocellular carcinoma; radioembolization; surgery; yttrium 90

Indexed keywords

ARTIFICIAL EMBOLIZATION; BILE DUCT CARCINOMA; CANCER RADIOTHERAPY; CANCER SURGERY; COMPARATIVE STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER HYPERTROPHY; LIVER RESECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SELECTIVE INTERNAL RADIATION THERAPY; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME; VOLUMETRY;

EID: 84992493213     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000449341     Document Type: Review

References (45)

1. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ: Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: A prospective randomized trial. Ann Surg 2007;245:36-43.
2. Cucchetti A, Bertuzzo V, Pinna AD: Can Positive Resection Margin of Intra-hepatic Cholangiocarcinoma Still Provide a Survival Benefit over Systemic Chemotherapy? World J Surg 2015;39:2965-2966
3. Wu CC, Cheng SB, Yeh DC, Wang J, P?eng FK: Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg 2009;96:1049-1057.
4. Zhou Y, Sui C, Li B, Yin Z, Tan Y, Yang J, Liu Z: Repeat hepatectomy for recurrent hepatocellular carcinoma: A local experience and a systematic review. World J Surg Oncol 2010;8:55.
5. Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K: Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg 2012;99:1711-1717.
6. Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL: Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015;4:16-25.
7. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S, European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY): Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 2011;54:868-878.
8. Khajornjiraphan N, Thu NA, Chow PK: Yttrium-90 microspheres: A review of its emerging clinical indications. Liver Cancer 2015;4:6-15.
9. Eshkenazy R, Dreznik Y, Lahat E, Zakai BB, Zendel A, Ariche A: Small for size liver remnant following resection: prevention and management. Hepatobiliary Surg Nutr 2014;3:303-312.
10. Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG: Hepatic radioembolization as a bridge to liver surgery. Front Oncol 2014;4:199.
11. Soydal C, Kucuk ON, Bilgic S, Ibis E: Radioembolization with 90Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med 2016;30:29-34.
12. Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O: Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol 2015;42:59-64.
13. Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS: Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol 2014;25:256-265.
14. Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, Kim HS: Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013;36:440-448.
15. Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, Ryu RK, Salem R, Lewandowski RJ: Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013;24:1227-1234.
16. Hoffmann RT, Paprottka PM, Schön A, Bamberg F, Haug A, Dörr EM, Rauch B, Trumm CT, Jakobs TF, Helmberger TK, Reiser MF, Kolligs FT: Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012;35:105-116.
17. Haug AR, Heinemann V, Bruns CJ, Hoffmann R, Jakobs T, Bartenstein P, Hacker M: 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging 2011;38:1037-1045.
18. Saxena A, Bester L, Chua TC, Chu FC, Morris DL: Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option. Ann Surg Oncol 2010;17:484-491.
19. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, Benson A 3rd, Omary RA, Salem R: Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008;113:2119-2128.
20. Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, Boucher E, Boudjema K: Intra-Arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 2015;22:3102-3108.
21. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C: Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 2013;57:1826-1837.
22. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB 3rd, Mulcahy MF: Radioembolization results in longer time-To-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507, e2.
23. Hilgard P, Hamami M, Fouly AE, Scherag A, Möller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G: Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-Term survival. Hepatology 2010;52:1741-1749.
24. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L: Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-Term outcomes. Gastroenterology 2010;138:52-64.
25. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS: Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:224-230.
26. Carr BI, Kondragunta V, Buch SC, Branch RA: Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: A two-cohort study. Cancer 2010;116:1305-1314.
27. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R: A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-1928.
28. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A 3rd, Nemcek AA Jr, Gates VL, Abecassis M, Omary RA, Salem R: Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81.
29. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J: Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66:792-800.
30. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG: Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005;16:1627-1639.
31. Carr BI: Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10(Suppl 1):S107-S110.
32. Bishay V, Edwards M, Lo G, Patel RS, Fischman AM, Kim E, Nowakowski F, Lookstein RA: Hypertrophy of future liver remnant in unresectable liver cancer following radioembolization with resin microspheres. J Vasc Interv Radiol 2015;2:S91.
33. Theysohn JM, Ertle J, Möller S, Schlaak JF, Nensa F, Sipilae S, Bockisch A, Lauenstein TC: Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol 2014;69:172-178.
34. Teo JY, Goh BK, Cheah FK, Allen JC, Lo RH, Ng DC, Goh AS, Khor AY, Sim HS, Ng JJ, Chow PK: Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma. J Dig Dis 2014;15:444-450.
35. Fernández-Ros N, Silva N, Bilbao JI, Iñarrairaegui M, Benito A, D?Avola D, Rodriguez M, Rotellar F, Pardo F, Sangro B: Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. HPB Oxf 2014;16:243-249.
36. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R: Radiation lobectomy: Timedependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013;59:1029-1036.
37. Ahmadzadehfar H, Meyer C, Ezziddin S, Sabet A, Hoff-Meyer A, Muckle M, Logvinski T, Schild HH, Biersack HJ, Wilhelm K: Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 2013;40:80-90.
38. Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, Pracht M, Raoul JL, Clément B, Garin E, Boucher E: Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: An option to portal vein embolization in a preoperative setting? Ann Surg Oncol 2013;20:2518-2525.
39. Garlipp B, de Baere T, Damm R, Irmscher R, van Buskirk M, Stöbs P, Deschamps F, Meyer F, Seidensticker R, Mohnike K, Pech M, Amthauer H, Lippert H, Ricke J, Seidensticker M: Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology 2014;59:1864-1873.
40. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R: Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009;16:1587-1596.
41. Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S: Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg 1986;10:803-808.
42. Sugawara Y, Yamamoto J, Higashi H, Yamasaki S, Shimada K, Kosuge T, Takayama T, Makuuchi M: Preoperative portal embolization in patients with hepatocellular carcinoma. World J Surg 2002;26:105-110.
43. van Lienden KP, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM, van Delden OM: Portal vein embolization before liver resection: A systematic review. Cardiovasc Intervent Radiol 2013;36:25-34.
44. Loffroy R, Favelier S, Chevallier O, Estivalet L, Genson PY, Pottecher P, Gehin S, Krausé D, Cercueil JP: Preoperative portal vein embolization in liver cancer: indications, techniques and outcomes. Quant Imaging Med Surg 2015;5:730-739.
45. Loveman E, Jones J, Clegg AJ, Picot J, Colquitt JL, Mendes D, Breen DJ, Moore E, George S, Poston G, Cunningham D, Ruers T, Primrose J: The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol Assess 2014;18:vii-viii, 1-283.